Log In
BCIQ
Print this Print this
 

biglycan (TVN-102)

  Manage Alerts
Collapse Summary General Information
Company Tivorsan Pharmaceuticals Inc.
DescriptionRecombinant human biglycan (rhBGN)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation U.S. - Orphan Drug (Treat Duchenne muscular dystrophy (DMD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1.5M

$1.5M

0


 Deals Details
Get a free BioCentury trial today